Literature DB >> 18337767

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

L S Steelman1, S L Abrams, J Whelan, F E Bertrand, D E Ludwig, J Bäsecke, M Libra, F Stivala, M Milella, A Tafuri, P Lunghi, A Bonati, A M Martelli, J A McCubrey.   

Abstract

Mutations and chromosomal translocations occur in leukemic cells that result in elevated expression or constitutive activation of various growth factor receptors and downstream kinases. The Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways are often activated by mutations in upstream genes. The Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways are regulated by upstream Ras that is frequently mutated in human cancer. Recently, it has been observed that the FLT-3 and Jak kinases and the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) phosphatase are also frequently mutated or their expression is altered in certain hematopoietic neoplasms. Many of the events elicited by the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways have direct effects on survival pathways. Aberrant regulation of the survival pathways can contribute to uncontrolled cell growth and lead to leukemia. In this review, we describe the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT signaling cascades and summarize recent data regarding the regulation and mutation status of these pathways and their involvement in leukemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337767     DOI: 10.1038/leu.2008.26

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  156 in total

1.  Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins.

Authors:  Scott Nadeau; Wei An; Nick Palermo; Dan Feng; Gulzar Ahmad; Lin Dong; Gloria E O Borgstahl; Amarnath Natarajan; Mayumi Naramura; Vimla Band; Hamid Band
Journal:  Biochem Anal Biochem       Date:  2012-07-30

Review 2.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

Review 3.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

Review 4.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

Review 5.  Phosphoinositide 3-kinase inhibitors in lymphoma.

Authors:  Emily Curran; Sonali M Smith
Journal:  Curr Opin Oncol       Date:  2014-09       Impact factor: 3.645

6.  Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.

Authors:  Tamer A Ahmed; John Hayslip; Markos Leggas
Journal:  Leuk Res       Date:  2014-09-16       Impact factor: 3.156

7.  Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.

Authors:  Matthew J Frank; David W Dawson; Steven J Bensinger; Jason S Hong; Wendy M Knosp; Lizhong Xu; Cynthia E Balatoni; Eric L Allen; Rhine R Shen; Dafna Bar-Sagi; Gail R Martin; Michael A Teitell
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113

Review 8.  Never say die: survival signaling in large granular lymphocyte leukemia.

Authors:  Mithun Vinod Shah; Ranran Zhang; Thomas P Loughran
Journal:  Clin Lymphoma Myeloma       Date:  2009

Review 9.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

10.  High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases.

Authors:  Velia D'Angelo; Stefania Crisci; Fiorina Casale; Raffaele Addeo; Maria Giuliano; Elvira Pota; Paola Finsinger; Alfonso Baldi; Roberto Rondelli; Alberto Abbruzzese; Michele Caraglia; Paolo Indolfi
Journal:  J Exp Clin Cancer Res       Date:  2009-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.